Last reviewed · How we verify
IOPIZE© Latanoprost eyedrops
IOPIZE© Latanoprost eyedrops is a Prostaglandin F analog Small molecule drug developed by University of Catanzaro. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: IOPIZE© eyedrops (S.I.F.I. S.p.A. - Aci S. Antonio (CT), Italy), authorization numbers:, 039276011, 039276023.
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | IOPIZE© Latanoprost eyedrops |
|---|---|
| Also known as | IOPIZE© eyedrops (S.I.F.I. S.p.A. - Aci S. Antonio (CT), Italy), authorization numbers:, 039276011, 039276023, 039276035 |
| Sponsor | University of Catanzaro |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost is a selective agonist of the prostaglandin F (FP) receptor located on the ciliary muscle bundle and trabecular meshwork of the eye. By activating these receptors, it enhances drainage of aqueous humor through the unconventional uveoscleral pathway, leading to decreased intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOPIZE© Latanoprost eyedrops CI brief — competitive landscape report
- IOPIZE© Latanoprost eyedrops updates RSS · CI watch RSS
- University of Catanzaro portfolio CI
Frequently asked questions about IOPIZE© Latanoprost eyedrops
What is IOPIZE© Latanoprost eyedrops?
How does IOPIZE© Latanoprost eyedrops work?
What is IOPIZE© Latanoprost eyedrops used for?
Who makes IOPIZE© Latanoprost eyedrops?
Is IOPIZE© Latanoprost eyedrops also known as anything else?
What drug class is IOPIZE© Latanoprost eyedrops in?
What development phase is IOPIZE© Latanoprost eyedrops in?
What are the side effects of IOPIZE© Latanoprost eyedrops?
What does IOPIZE© Latanoprost eyedrops target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor)
- Manufacturer: University of Catanzaro — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: IOPIZE© eyedrops (S.I.F.I. S.p.A. - Aci S. Antonio (CT), Italy), authorization numbers:, 039276011, 039276023, 039276035
- Compare: IOPIZE© Latanoprost eyedrops vs similar drugs
- Pricing: IOPIZE© Latanoprost eyedrops cost, discount & access